for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ProMetic Life Sciences Inc.

PLI.TO

Latest Trade

13.40CAD

Change

0.39(+3.00%)

Volume

7,954

Today's Range

12.52

 - 

13.60

52 Week Range

7.13

 - 

590.00

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
13.01
Open
12.95
Volume
7,954
3M AVG Volume
0.36
Today's High
13.60
Today's Low
12.52
52 Week High
590.00
52 Week Low
7.13
Shares Out (MIL)
23.31
Market Cap (MIL)
303.30
Forward P/E
-0.28
Dividend (Yield %)
--

Latest Developments

More

Prometic Life Sciences Q2 Revenue C$8.8 Million

Prometic Reports Its 2019 First Quarter Financial Results

Prometic Life Sciences Says Kenneth Galbraith Appointed CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ProMetic Life Sciences Inc.

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Industry

Biotechnology & Drugs

Contact Info

440 Armand-Frappier Blvd Bureau 300

+1.450.7810115

https://prometic.com/

Executive Leadership

Simon Geoffrey Best

Interim Chief Executive Officer

Bruce Pritchard

Interim Chief Financial Officer, Chief Operating Officer

John Moran

Chief Medical Officer, Director

Patrick Sartore

Chief Legal Officer and Corporate Secretary

Gary J. Bridger

Director

Key Stats

3.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (CAD)

2016

-170.000

2017

-180.000

2018

-60.000

2019(E)

-46.515
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.60
Price To Book (MRQ)
2.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
35.57
LT Debt To Equity (MRQ)
29.08
Return on Investment (TTM)
-171.61
Return on Equity (TTM)
-140.99

Latest News

BRIEF-ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial

* ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: Further company coverage:

BRIEF-Prometic's PBI-4050 demonstrates early evidence of efficacy in its IPF Phase 2 clinical trial

* Early evidence of efficacy of PBI-4050 alone and also in combination with one of commercially available IPF drugs

BRIEF-Prometic life sciences PBI-4050 shown to reduce pulmonary hypertension

* Prometic Life Sciences - PBI-4050 shown to reduce pulmonary hypertension and lung remodeling and to improve right ventricular function in heart failure

BRIEF-Prometic announces closing of Telesta Therapeutics acquisition

* Prometic announces closing of Telesta Therapeutics Inc Acquisition Source text for Eikon: Further company coverage:

BRIEF-Telesta Therapeutics announces final court approval of plan of arrangement with Prometic Life Sciences

* Announces final court approval of plan of arrangement with Prometic Life Sciences Inc

BRIEF-Telesta Therapeutics shareholders approve plan of arrangement with Prometic Life Sciences

* Telesta Therapeutics Inc. shareholders approve plan of arrangement with Prometic Life Sciences Inc.

BRIEF-Prometic's PBI-4050 meets primary end point

* Prometic's PBI-4050 meets primary and secondary end points in metabolic syndrome and type 2 diabetes phase 2 clinical trial

BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

* Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

BRIEF-Telesta says ISS, Glass Lewis recommend shareholders vote for plan of arrangement between co, Prometic Life Sciences

* Leading independent advisory firms ISS and Glass Lewis recommend shareholders vote for the plan of arrangement Between Telesta Therapeutics Inc and Prometic Life Sciences Inc Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up